FibCLOT, a new human fibrinogen concentrate is now available in the UK, offering increased therapeutic choices for patients affected by congenital fibrinogen deficiency.
FibCLOT, manufactured and marketed by LFB, is indicated for the treatment and perioperative prophylaxis of bleeding in patients with congenital hypo- or afibrinogenaemia with a tendency to bleed. A clinical study in children has also recently been completed, with the largest cohort of paediatric patients ever included in such a trial to date.
Congenital fibrinogen deficiency is a rare, potentially life- threatening genetic bleeding disorder affecting approximately one in a million people. As fibrinogen, also known as Factor I, is necessary for blood clot formation, reduced, absent or abnormal amounts of fibrinogen affect the body’s ability to form a clot effectively. Symptoms of congenital fibrinogen deficiency include excessive bleeding following an injury, surgery or childbirth, nosebleeds, mouth bleeds, easy bruising, bleeding of the umbilical cord at birth, spontaneous bleeding, joint or mouth bleeds and problems during pregnancy.
Further information is available on the LFB website.